证券日报网讯中科信息（300678）9月26日在互动平台回答投资者提问时表示，目前，公司未参与阿里 云数据中心建设。 ...

格隆汇9月26日丨中科信息(300678.SZ)在投资者互动平台表示，目前，公司未参与阿里云数据中心建 设。 ...

格隆汇9月26日丨中科信息(300678.SZ)在投资者互动平台表示，目前，公司未参与阿里云数据中心建 设。 ...

Group 1 - The core theme of the forum was "Future Industries and State Capital Empowering Listed Companies," with over 300 listed companies and 250 state-owned representatives attending [2] - Zhongke Information was awarded the title of "Future Information Industry Star Listed Company" for its innovative practices and contributions to the industry [2] - The company has been a pioneer in using artificial intelligence to assist in the digital transformation of various sectors, including smart governance, intelligent manufacturing, smart cities, and smart healthcare [2][3] Group 2 - Zhongke Information is recognized as a leading enterprise in the artificial intelligence industry chain in Sichuan Tianfu New Area and has been selected as one of the first batch of "Intelligent Transformation and Digital Upgrade" suppliers in Sichuan Province [3] - The company has successfully developed and implemented several innovative products, including the EIOD edge intelligent industrial internet platform and various AI products for specific industries [3] - The company aims to focus on high-quality development, optimize its business layout, and enhance its operational and sustainable development capabilities to contribute to industry prosperity and the capital market's high-quality growth [3]

Core Viewpoint - Zhongke Information (300678) has been awarded the "A-share ESG Demonstration Case" honor at the 2025 China Listed Company Yinghua Awards, reflecting its excellence in environmental, social, and governance (ESG) practices [1][2] Group 1: ESG Recognition - The award encompasses both A-share and Hong Kong stock markets, with 15 categories established to evaluate companies based on authoritative and objective criteria [1] - Evaluation metrics include institutional investor recommendations, expert reviews, and public opinion data, focusing on "intrinsic value, growth potential, value companionship, and value harvest" [1] - The recognition highlights the capital market's acknowledgment of the company's standardized governance and its role in empowering green development through AI [1] Group 2: Company Initiatives - Zhongke Information has been committed to the implementation of "AI+ applications" in areas such as smart government, intelligent manufacturing, smart cities, and smart healthcare [1] - The company has developed a series of digital products that support new productivity construction, including the EIOD edge intelligent internet platform, which provides comprehensive solutions for smart factories [1] - Products like machine vision models and data analysis algorithms have enhanced quality and precision in industries such as banknote printing, card manufacturing, glass, and lithium batteries [1] - Intelligent emergency rescue, drone patrol, and smart operation and maintenance products offer safety guarantees in oil and gas fields and pipeline networks [1] Group 3: Future Commitment - The company will continue to uphold sustainable development principles, aiming to meet national major needs and assist industries in improving quality and efficiency [2] - Zhongke Information is dedicated to enhancing its ESG management level and actively fulfilling social responsibilities [2] - The company aims to contribute to the green low-carbon and digital transformation of the industry [2]

中科信息（300678.SZ）9月24日在投资者互动平台表示，公司紧密结合行业需求，自主研发了面向医疗 领域的智能麻醉机器人和面向建造领域的智能装载、智能铺路机器人。目前，智能麻醉机器人已成功完 成首例临床试验，同步进行第三类医疗器械的认证；智能装载机器人、智能铺路机器人是综合机器视觉 与智能分析、自动驾驶、工程施工全自动化技术、雷达通讯技术的多模态产品，智能装载机器人（一 期）已进入试用阶段，智能铺路机器人正处于测试阶段。公司高速机器视觉与智能分析技术适用性广 泛，可应用于多个行业领域，目前无人形机器人相关业务。关于公司业务、研发进展等情况，请关注公 司定期报告等公告。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司的机器视觉有没有考虑运用到人形机器人身上， 有没有和国际国内头部人形机器人公司开展合作？ ...

Group 1 - The A-share market saw a significant decline in brain-computer interface concept stocks, with several companies experiencing drops of over 5% [1] - Notable companies that fell over 5% include Dineike, Xiangyu Medical, Meihao Medical, Chengdu Huamei, and Tom Cat [1] - Other companies such as Yanshan Technology, Zhongke Information, Aipeng Medical, Nanjing Panda, Weisi Medical, Innovation Medical, Robot, Mailande, Beiqingsong, Botuo Biological, and Rongtai Health dropped over 4% [1]

Group 1: Company Ownership and Control - The actual controller, China Academy of Sciences Holdings Co., Ltd. (CAS Holdings), directly holds 30.53% of the company's shares, maintaining absolute control and leadership [3] - CAS Holdings positions the company as a leader in the artificial intelligence sector, providing resource support [3] Group 2: Strategic Partnerships - The company has had a strategic partnership with West China Hospital for nearly twenty years, focusing on deep collaboration across various departments [4] - The partnership leverages medical big data and artificial intelligence technologies to create specialized solutions and products [4] Group 3: Product Development and Commercialization - The intelligent anesthesia robot has successfully completed its first clinical trial, with plans to obtain Class III medical device certification by the end of 2028 [5] - The company is developing a comprehensive solution for smart hospitals centered around the intelligent anesthesia robot and tumor adaptive radiotherapy platform [5] - The intelligent loading robot is currently in trial use within the Road and Bridge Group, with market promotion underway [6][7] Group 4: Revenue Sources and Business Segments - The main revenue sources include the tobacco business (28%-35% of revenue) and digital conference services (26%-32% of revenue), with other contributions from government, energy, and healthcare sectors [8] - The company has not yet developed brain-computer interface (BCI) technology but is exploring its application in smart medical services [9] Group 5: Technological Advancements and Research - The company has established a doctoral and master's training program at the University of the Chinese Academy of Sciences, supported by an automated reasoning laboratory led by academicians [11] - It has developed a full industrial chain layout for machine vision, ensuring the integration of basic research, key technologies, and industry applications [11]

Group 1: Financial Performance - The company reported a significant increase in new contracts, with a growth rate of 280% in the first half of 2025 compared to the previous year, driven by various business segments [6][25] - The gross profit margin for Q1 2025 was 38.38%, a notable increase from 20.62% for the entire year of 2024, attributed to contributions from multiple business sectors [3][8] - Revenue from the tobacco sector increased by 35.56%, while the oil and gas information sector saw a remarkable growth of 95.85% [25] Group 2: Business Strategy and Market Development - The company is focusing on high-quality development and value maintenance through a strict market value management approach [3][24] - Plans to enhance collaboration with Tesla in the humanoid robot sector were discussed, leveraging the company's expertise in machine vision technology [4][16] - The company aims to expand its market presence in smart healthcare and smart city projects, aligning with national digital transformation initiatives [25][5] Group 3: Product Development and Innovation - The intelligent anesthesia robot has successfully completed its first clinical trial, with ongoing certification processes for medical device registration [9][19] - The company is actively developing a complete AI industrial chain, integrating edge computing and data platforms to support the intelligent anesthesia robot's capabilities [22][28] - The company has established partnerships with various institutions, including Sichuan University Huaxi Hospital, to enhance product development and clinical applications [21][9] Group 4: Investor Relations and Communication - The company emphasizes the importance of investor relations, aiming to enhance understanding and recognition of its value among investors [24][25] - Regular updates and disclosures regarding capital operations and market strategies will be provided to maintain transparency [23][25]

Core Insights - The company focuses on smart healthcare as a strategic business area, engaging in smart hospitals, regional medical services, medical IoT, and AI medical devices [1] - The company has developed a medical large model in collaboration with Sichuan University West China Hospital, primarily for training intelligent anesthesia robots, with successful completion of the first clinical trial [1] - The company has established a laboratory for brain cognition and smart medical applications in Chengdu, focusing on key technologies in AI and medical engineering [1] Financial Performance - In the first half of 2025, the company achieved revenue of 142 million yuan, a year-on-year decrease of 6.61% [2] - The company reported a net profit attributable to shareholders of 4 million yuan, down 24.48% year-on-year [2]